Literature DB >> 23928359

Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose.

M J Dooley1, S G Poole, D Rischin.   

Abstract

BACKGROUND: Oncology clinicians are now routinely provided with an estimated glomerular filtration rate on pathology reports whenever serum creatinine is requested. The utility of using this for the dose determination of renally excreted drugs compared with other existing methods is needed to inform practice. PATIENTS AND METHODS: Renal function was determined by [Tc(99m)]DTPA clearance in adult patients presenting for chemotherapy. Renal function was calculated using the 4-variable Modification of Diet in Renal Disease (4v-MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Cockcroft and Gault (CG), Wright and Martin formulae. Doses for renal excreted cytotoxic drugs, including carboplatin, were calculated.
RESULTS: The concordance of the renal function estimates according to the CKD classification with measured Tc(99m)DPTA clearance in 455 adults (median age 64.0 years: range 17-87 years) for the 4v-MDRD, CKD-EPI, CG, Martin and Wright formulae was 47.7%, 56.3%, 46.2%, 56.5% and 60.2%, respectively. Concordance for chemotherapy dose for these formulae was 89.0%, 89.5%, 85.1%, 89.9% and 89.9%, respectively. Concordance for carboplatin dose specifically was 66.4%, 71.4%, 64.0%, 73.8% and 73.2%.
CONCLUSION: All bedside formulae provide similar levels of concordance in dosage selection for the renal excreted chemotherapy drugs when compared with the use of a direct measure of renal function.

Entities:  

Keywords:  carboplatin; chemotherapy; dose; glomerular filtration rate; renal function

Mesh:

Substances:

Year:  2013        PMID: 23928359     DOI: 10.1093/annonc/mdt300

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Authors:  Hassan Izzedine; Mark A Perazella
Journal:  Nephrol Dial Transplant       Date:  2015-02-03       Impact factor: 5.992

2.  Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies.

Authors:  Pierre Delanaye; Fabrice Guerber; André Scheen; Timothy Ellam; Antoine Bouquegneau; Dorra Guergour; Christophe Mariat; Hans Pottel
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

Review 3.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

Review 4.  GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.

Authors:  Blaithin A McMahon; Mitchell H Rosner
Journal:  Kidney360       Date:  2020-01-13

5.  Improving Carboplatin Dosing Based on Estimated GFR.

Authors:  Jan H Beumer; Lesley A Inker; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2017-12-06       Impact factor: 8.860

6.  Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events.

Authors:  Justin Lawson; Jeffrey M Switchenko; Trevor McKibbin; R Donald Harvey
Journal:  Pharmacotherapy       Date:  2016-06       Impact factor: 4.705

7.  Creatinine-based equations for the adjustment of drug dosage in an obese population.

Authors:  Antoine Bouquegneau; Emmanuelle Vidal-Petiot; Olivier Moranne; Christophe Mariat; Jean-Jacques Boffa; François Vrtovsnik; André-Jean Scheen; Jean-Marie Krzesinski; Martin Flamant; Pierre Delanaye
Journal:  Br J Clin Pharmacol       Date:  2016-01-17       Impact factor: 4.335

8.  Serial renography for evaluation of the impact of capecitabine therapy on renal function: A case report.

Authors:  Jiazhong Ren; Zongwei Huo; Xiaohui Wang; Yan Liu; Guoren Yang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.